The DOI matches its Crossref record; 226 of the 226 references it cites were found in a registry or an index.
Immunotherapy: Reshape the Tumor Immune Microenvironment
Open accessAbstract
Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc. The interactions between these components, which are divided into anti-tumor and pro-tumor, determine the trend of anti-tumor immunity. Although the immune system can eliminate tumor through the cancer-immune cycle, tumors appear to eventually evade from immune surveillance by shaping an immunosuppressive microenvironment. Immunotherapy reshapes the TIME and restores the tumor killing ability of anti-tumor immune cells. Herein, we review the function of immune cells within the TIME and discuss the contribution of current mainstream immunotherapeutic approaches to remolding the TIME. Changes in the immune microenvironment in different forms under the intervention of immunotherapy can shed light on better combination treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–226 of 226
Type 2 Innate Lymphoid Cells Impede IL-33–Mediated Tumor Suppression
Long, A., Dominguez, D., Qin, L., Chen, S., Fan, J., Zhang, M., Fang, D., Zhang, Y., Kuzel, T. M., & Zhang, B. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800173 · Cited by 78
Sitkovsky, M. V. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1280 · Cited by 77
Song, W., & Zhang, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108382 · Cited by 75
Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
Hatfield, S. M., & Sitkovsky, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137554 · Cited by 73
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
Mehta, N., Maddineni, S., Kelly, R. L., Lee, R., Yamada‐Hunter, S. A., Silberstein, J. L., Sperberg, R. A. P., Miller, C. L., Rabe, A., Labanieh, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71519-4 · Cited by 68
Sang, W., Wang, X., Geng, H., Li, T., Li, D., Zhang, B., Zhou, Y., Song, X., Sun, C., Yan, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.858021 · Cited by 64
Scholz, M. C., Yep, S., Chancey, M., Kelly, C., Chau, K., Turner, J., Lam, R. Y., & Drake, C. G. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s122497 · Cited by 59
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
Zahm, C. D., Moseman, J. E., Delmastro, L. E., & McNeel, D. G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1912892 · Cited by 57
Immune checkpoints and cancer development: Therapeutic implications and future directions
Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 56
The Role of Tumor Associated Macrophages in the Tumor Microenvironment: Mechanism and Functions
Zhu, J., Zhi, Q., Zhou, B. P., Tao, M., Liu, J., & Li, W. (2016) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520616666160520112622 · Cited by 54
Self-citationFriend or Foe? The Ambiguous Role of Innate Lymphoid Cells in Cancer Development
Mattner, J., & Wirtz, S. J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.10.004 · Cited by 52
The dark side of immunotherapy
Okwundu, N., Grossman, D., Hu‐Lieskovan, S., Grossmann, K. F., & Swami, U. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4750 · Cited by 52
Lozano, E., Mena, M.-P., Díaz, T., Martín-Antonio, B., León, S., Rodríguez‐Lobato, L. G., Oliver‐Caldés, A., Cibeira, M. T., Bladé, J., Prat, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3673 · Cited by 47
Ngiow, S. F., Meeth, K. M., Stannard, K. A., Barkauskas, D. S., Bollag, G. E., Bosenberg, M., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1089381 · Cited by 45
Sorrentino, C., Miele, L., Porta, A., Pinto, A., & Morello, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11729 · Cited by 45
A Redox‐Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy
Yan, P., Luo, Y., Li, X., Li, Y., Wang, Y., Wu, J., & Zhou, S. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101222 · Cited by 45
Self-citationMangiameli, D. P., Blansfield, J., Kachala, S., Lorang, D., Schafer, P. H., Muller, G. W., Stirling, D., & Libutti, S. K. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-38 · Cited by 44
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
Hayes, G. M., Cairns, B., Levashova, Z. B., Chinn, L., Perez, M., Theunissen, J.-W. F., Liao-Chan, S., Bermudez, A., Flory, M. R., Schweighofer, K. J., et al. (2015) · PubMed Central · Cited by 41
Omstead, A. N., Paskewicz, M., Gorbunova, A., Zheng, P., Salvitti, M. S., Mansoor, R., Reed, P., Ballengee, S., Wagner, P. L., Jobe, B. A., et al. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac043 · Cited by 37
Chen, Q., Wang, J., Chen, W., Zhang, Q., Wei, T., Zhou, Y., Xu, X., Bai, X., & Liang, T. (2018) · Cancer Science · doi:10.1111/cas.13914 · Cited by 34
Hatfield, S. M., & Sitkovsky, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052934 · Cited by 31
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
Qu, Q., Zhai, Z., Xu, J., Li, S., Chen, C., & Lu, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00634 · Cited by 31
Advances in Chimeric Antigen Receptor T‐Cell Therapies for Solid Tumors
Baybutt, T. R., Flickinger, J. C., Caparosa, E. M., & Snook, A. E. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1280 · Cited by 29
Group 2 Innate Lymphoid Cells: A Double-Edged Sword in Cancer?
Maggi, E., Veneziani, I., Moretta, L., Cosmi, L., & Annunziato, F. (2020) · Cancers · doi:10.3390/cancers12113452 · Cited by 27
Surufatinib — a novel oral agent for neuroendocrine tumours
Koumarianou, A. A., & Kaltsas, G. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00439-0 · Cited by 21
Small Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
Cited by
The role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
Choi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Metadata
- Authors
- LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-07-06
- Volume
- 13
- Pages
- 844142-844142
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4286629873
- Cited by
- 482
- References
- 226
- FWCI
- 37.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.